Study summary
Iza-bren beat chemotherapy as a second treatment
36% lowerrisk of death vs chemotherapy
What was tested
Iza-bren (izalontamab brengitecan), an antibody that carries chemotherapy to tumor cells, against standard single-drug chemotherapy. For people whose cancer grew after immunotherapy plus platinum chemotherapy.
What they found
- Typical survival was 9.8 months with iza-bren and 7.2 months with chemotherapy (hazard ratio 0.64).
- Time before the cancer grew was 4.2 vs 2.0 months.
- Serious treatment side effects were more common with iza-bren: 85% vs 60%.
- Serious lung inflammation was rare (0.8%).
What it means
The first drug of its kind to beat chemotherapy in this cancer. It is approved in China only; no filing elsewhere has been announced.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.